- Home
- NAD vs TMDX Comparison
NAD vs TMDX Comparison
Compare NAD & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAD
- TMDX
- Stock Information
- Founded
- NAD 1999
- TMDX 1998
- Country
- NAD United States
- TMDX United States
- Employees
- NAD N/A
- TMDX N/A
- Industry
- NAD Investment Managers
- TMDX Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- NAD Finance
- TMDX Health Care
- Exchange
- NAD Nasdaq
- TMDX Nasdaq
- Market Cap
- NAD 2.8B
- TMDX 2.4B
- IPO Year
- NAD N/A
- TMDX 2019
- Fundamental
- Price
- NAD $11.89
- TMDX $71.95
- Analyst Decision
- NAD
- TMDX Buy
- Analyst Count
- NAD 0
- TMDX 11
- Target Price
- NAD N/A
- TMDX $116.10
- AVG Volume (30 Days)
- NAD 595.7K
- TMDX 1.3M
- Earning Date
- NAD 01-01-0001
- TMDX 02-27-2025
- Dividend Yield
- NAD 4.35%
- TMDX N/A
- EPS Growth
- NAD N/A
- TMDX N/A
- EPS
- NAD N/A
- TMDX 0.94
- Revenue
- NAD N/A
- TMDX $401,090,000.00
- Revenue This Year
- NAD N/A
- TMDX $81.61
- Revenue Next Year
- NAD N/A
- TMDX $22.52
- P/E Ratio
- NAD N/A
- TMDX $76.78
- Revenue Growth
- NAD N/A
- TMDX 109.09
- 52 Week Low
- NAD $9.56
- TMDX $55.00
- 52 Week High
- NAD $11.64
- TMDX $177.37
- Technical
- Relative Strength Index (RSI)
- NAD 55.74
- TMDX 52.52
- Support Level
- NAD $11.70
- TMDX $66.81
- Resistance Level
- NAD $11.92
- TMDX $80.00
- Average True Range (ATR)
- NAD 0.07
- TMDX 4.14
- MACD
- NAD 0.00
- TMDX 0.57
- Stochastic Oscillator
- NAD 77.08
- TMDX 48.74
About NAD Nuveen Quality Municipal Income Fund
Nuveen Quality Municipal Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide current income exempted from regular federal income tax by investing in tax-exempt municipal securities that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.
About TMDX TransMedics Group Inc.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.